| pubmed-article:10843744 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10843744 | lifeskim:mentions | umls-concept:C0684336 | lld:lifeskim |
| pubmed-article:10843744 | lifeskim:mentions | umls-concept:C0023890 | lld:lifeskim |
| pubmed-article:10843744 | lifeskim:mentions | umls-concept:C0232741 | lld:lifeskim |
| pubmed-article:10843744 | lifeskim:mentions | umls-concept:C0040690 | lld:lifeskim |
| pubmed-article:10843744 | lifeskim:mentions | umls-concept:C1522602 | lld:lifeskim |
| pubmed-article:10843744 | lifeskim:mentions | umls-concept:C0175630 | lld:lifeskim |
| pubmed-article:10843744 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:10843744 | pubmed:dateCreated | 2000-8-23 | lld:pubmed |
| pubmed-article:10843744 | pubmed:abstractText | In the liver, transforming growth factor (TGF) -beta(1)is primarily responsible for activation of fat-storing cells, which are the main source of extracellular matrix proteins. Their deposition play a key role in the development of liver cirrhosis. The aim of this study was to evaluate plasma TGF-beta(1)in patients with different stages of liver cirrhosis and its possible use as an indicator of liver function impairment. TGF-beta(1)was measured in the plasma of 40 patients with liver cirrhosis. To estimate possible effect of liver insufficiency on plasma TGF-beta(1), patients were divided into three groups: A, B and C, univocal with Child-Pugh classes. Normal values were collected from 13 healthy volunteers. Liver cirrhosis resulted in a significant increase of plasma concentration of TGF-beta(1)(39.3+/-3.8 ng/ml), which doubled normal values (18.3+/-1.6 ng/ml). The highest concentrations were observed in alcoholic patients (44.4+/-4.7 ng/ml). TGF-beta(1)level increased depending on the degree of liver insufficiency, demonstrated by a significant positive correlation with Child-Pugh score (r=0.591). Values in group A were similar to normal, but were significantly elevated in groups B and C. These findings suggest possible use of plasma TGF-beta(1)measurement as an indicator of liver function impairment and possible marker of hepatic fibrosis progression in cirrhotic patients. | lld:pubmed |
| pubmed-article:10843744 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10843744 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10843744 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10843744 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10843744 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10843744 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10843744 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10843744 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10843744 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10843744 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:10843744 | pubmed:issn | 1043-4666 | lld:pubmed |
| pubmed-article:10843744 | pubmed:author | pubmed-author:ProkopowiczDD | lld:pubmed |
| pubmed-article:10843744 | pubmed:author | pubmed-author:FlisiakRR | lld:pubmed |
| pubmed-article:10843744 | pubmed:author | pubmed-author:Pytel-Krolczu... | lld:pubmed |
| pubmed-article:10843744 | pubmed:copyrightInfo | Copyright 2000 Academic Press. | lld:pubmed |
| pubmed-article:10843744 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10843744 | pubmed:volume | 12 | lld:pubmed |
| pubmed-article:10843744 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10843744 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10843744 | pubmed:pagination | 677-81 | lld:pubmed |
| pubmed-article:10843744 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:10843744 | pubmed:meshHeading | pubmed-meshheading:10843744... | lld:pubmed |
| pubmed-article:10843744 | pubmed:meshHeading | pubmed-meshheading:10843744... | lld:pubmed |
| pubmed-article:10843744 | pubmed:meshHeading | pubmed-meshheading:10843744... | lld:pubmed |
| pubmed-article:10843744 | pubmed:meshHeading | pubmed-meshheading:10843744... | lld:pubmed |
| pubmed-article:10843744 | pubmed:meshHeading | pubmed-meshheading:10843744... | lld:pubmed |
| pubmed-article:10843744 | pubmed:meshHeading | pubmed-meshheading:10843744... | lld:pubmed |
| pubmed-article:10843744 | pubmed:meshHeading | pubmed-meshheading:10843744... | lld:pubmed |
| pubmed-article:10843744 | pubmed:meshHeading | pubmed-meshheading:10843744... | lld:pubmed |
| pubmed-article:10843744 | pubmed:meshHeading | pubmed-meshheading:10843744... | lld:pubmed |
| pubmed-article:10843744 | pubmed:meshHeading | pubmed-meshheading:10843744... | lld:pubmed |
| pubmed-article:10843744 | pubmed:meshHeading | pubmed-meshheading:10843744... | lld:pubmed |
| pubmed-article:10843744 | pubmed:meshHeading | pubmed-meshheading:10843744... | lld:pubmed |
| pubmed-article:10843744 | pubmed:meshHeading | pubmed-meshheading:10843744... | lld:pubmed |
| pubmed-article:10843744 | pubmed:meshHeading | pubmed-meshheading:10843744... | lld:pubmed |
| pubmed-article:10843744 | pubmed:meshHeading | pubmed-meshheading:10843744... | lld:pubmed |
| pubmed-article:10843744 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:10843744 | pubmed:articleTitle | Circulating transforming growth factor beta(1) as an indicator of hepatic function impairment in liver cirrhosis. | lld:pubmed |
| pubmed-article:10843744 | pubmed:affiliation | Department of Infectious Diseases, Medical Academy of Bialystok, Bialystok, Poland. flisiakr@priv.onet.pl | lld:pubmed |
| pubmed-article:10843744 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10843744 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10843744 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10843744 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10843744 | lld:pubmed |
